Significant Ownership of GILEAD SCIENCES, INC.

Signature - Title
/s/ Andrew D. Dickinson - Andrew D. Dickinson/Chief Financial Officer
Location
Foster City, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by GILEAD SCIENCES, INC..

Follow Filing Activity

Follow GILEAD SCIENCES, INC. and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sponsored

Significant Ownership of GILEAD SCIENCES, INC.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLPG Galapagos NV Ordinary Shares, no par value 30% $555,786,955 20,981,010 Gilead Sciences, Inc. 07 Jan 2025
ASMB ASSEMBLY BIOSCIENCES, INC. Common Stock, par value $0.001 29% 4,505,391 +104% GILEAD SCIENCES, INC. 08 Aug 2025
RCUS Arcus Biosciences, Inc. Common Stock, par value $0.0001 26% $427,376,736 31,424,760 0% GILEAD SCIENCES, INC. 03 Nov 2025
XLO Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share 20% $9,581,667 +$2,576,464 14,517,678 +37% GILEAD SCIENCES, INC. 31 Dec 2025
ACLX Arcellx, Inc. Common Stock, par value $0.001 12% $457,955,516 6,720,803 Gilead Sciences, Inc. 23 Feb 2026
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 per value 3.9% $4,715,740 723,273 GILEAD SCIENCES, INC. 18 Mar 2025
IKNA Ikena Oncology, Inc. Common Stock 3.6% $1,612,591 1,521,312 GILEAD SCIENCES INC 31 Dec 2024
CYPH CYPHERPUNK TECHNOLOGIES INC. Common Stock, par value $0.001 per share 0% $0 0 GILEAD SCIENCES, INC. 31 Dec 2025

Schedules 13D/G Reported by GILEAD SCIENCES, INC.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.